INTRODUCTION
Schizophrenia is a devastating mental illness which can seriously compromise the lives of those afflicted, as well as their caretakers and family members. Historically, the cause of this illness has been attributed to demonic possession, sinful behavior, bad parenting, or even the season of the year when the subject was born. Various and sundry interventions have been employed over the years to treat this illness including complete social isolation, insulin shock, and electroconvulsive therapy.
In 1952, the medication chlorpromazine was discovered to have beneficial effects on the positive symptoms of the illness (e.g., delusions, hallucinations, paranoia), ushering in a new era of development and understanding of the biological basis of schizophrenia. Chlorpromazine was demonstrated to block dopamine (D 2 ) receptors in the brain, leading researchers to speculate that the illness was caused by excessive dopaminergic activity. This crude understanding of the pathophysiology of schizophrenia was to become the foundation of subsequent drug development for many years.
Although chlorpromazine represented a major breakthrough in the humane management of the illness, it was also associated with a wide range of adverse effects, including sedation, anticholinergia, orthostasis, extrapyramidal side effects (EPS), and tardive dyskinesia. As these toxic phenomena were believed to be due to action of chlorpromazine on many neurotransmitter systems, drug development focused more intently upon dopaminergic systems, ultimately identifying compounds such as haloperidol and fluphenazine which possessed a high affinity for postsynaptic D 2 receptors. Clinically, these medications are less sedating than older compounds and lack anticholinergic effects, but the incidence and severity of EPS is much greater with these agents, resulting in additional discomfort, disability, and medication noncompliance.
What is an atypical antipsychotic?
Insight into the mechanisms of schizophrenia and implications for treatment were influenced dramatically by the discovery of clozapine. Clozapine was initially developed over 30 years ago as an antidepressant medication and was serendipitously discovered to possess antipsychotic properties. It was commonly prescribed in Europe for this purpose where a unique clinical profile began to emerge; clozapine appeared to cause few, if any, EPS and was associated with little or no risk of tardive dyskinesia. Furthermore, it appeared to be particularly effective for patients with treatment-refractory schizophrenia and demonstrated benefits for the negative symptoms of the disease (e.g., lack of motivation, poor hygiene, anergia) as well. During this time case reports of agranulocytosis began to accumulate, leading to the withdrawal of clozapine from many markets. The unprecedented therapeutic benefit of this medication was not forgotten, however, and it was re-released with strict blood monitoring guidelines thereafter.
Pharmacologically, clozapine possesses high affinity for a unique array of neurotransmitter systems (Fig. 1 ). It interacts with nine different receptors: D 2 , D 1 , D 4 , H 1 , M 1 , α 1 , 5-HT 2A , 5-HT 2C , and 5-HT 3 receptors. The basis for its efficacy in treating schizophrenia with a low risk for EPS is thought to result from its preferential activity at 5-HT 2A receptors and relatively low affinity for D 2 receptors. In positron emission tomography (PET) studies, doses of clozapine of 125-600 mg resulted in a 20-67% occupancy of D 2 receptors and an 84-94% occupancy of 5-HT 2A receptors (17, 51) . This is in contrast to conventional neuroleptics, which uniformly occupy D 2 receptors at a rate of 70-90% with therapeutic doses and possess essentially no blockade of 5-HT receptors (17) . This predominance of 5-HT 2A interaction over D 2 occupancy has been proposed to decrease the risk of EPS of this agent.
Furthermore, while conventional antipsychotics act nonselectively in the mesolimbic, mesocortical, nigrostriatal, and tuberoinfundibular dopamine pathways in the brain, data from animal models suggest that clozapine causes greater dopamine turnover in the limbic structures than in the striatum (66) . This anatomic specificity ultimately may determine the atypicality of an antipsychotic agent. Blockade of dopamine receptors in the mesolimbic pathway most likely contributes to the effect of an antipsychotic agent on po- sitive symptoms of schizophrenia, while blockade of the motor pathways in the nigrostriatal region and its projections to the basal ganglia will lead to the motor dysfunctions characteristic of EPS and tardive dyskinesia. Blockade of dopamine in the mesocortical pathway has been suggested to worsen cognitive dysfunction; alternatively, low activity in this pathway may be related to the negative symptoms of schizophrenia. In any case, D 2 receptor blockade in this pathway appears to negatively affect cognition and potentially higher cortical processing. Finally, blockade of dopamine in the tuberoinfundibular pathway results in a rise of prolactin secretion, potentially causing galactorrhea, disruption of normal ovulatory cycles, or amenorrhea, side effects seen with conventional and some atypical antipsychotics (16, 61) . Understanding of the neurochemistry and pathophysiology of schizophrenia has accelerated in recent years through a combination of in vitro binding studies, animal model research, and PET studies of patients with schizophrenia. Conventional antipsychotic agents have been the mainstay of treatment of this disease for many years; however, new information suggests that nonselectively blockade of D 2 receptors in multiple pathways of the brain contributes also to the serious neurologic adverse effects of these drugs. Our increasing understanding of the roles of 5-HT 2 receptors and activity in the various dopaminergic pathways in the brain have led to the development of new atypical antipsychotics with the distinctive pharmacologic profile of combined dopamine and serotonin blockade. Theoretically, such agents will have a lower risk of EPS at clinically relevant doses and an improved efficacy for the negative symptoms of schizophrenia. With high activity at 5-HT 2A and D 2 receptors, risperidone was the first atypical antipsychotic marketed in the United States after the introduction of clozapine.
PHARMACOLOGY
Risperidone is a benzisoxazole derivative that was developed as a result of improved understanding of the pharmacological principles at work in schizophrenia. In the mid-1980s, researchers discovered that the specific 5-HT 2 antagonist ritanserin improved the negative symptoms of schizophrenia and reduced EPS when administered with the conventional agent haloperidol (5) . Risperidone was the product of work designed to create the same pharmacologic profile as that created by combining ritanserin with haloperidol; that is, high affinity for D 2 and 5-HT 2 receptors in one agent.
In Vitro Studies
In vitro studies have compared risperidone and its primary active metabolite 9-OH-risperidone to other atypical and conventional antipsychotic agents (39, 60) (Tables 1-2) . Risperidone has a very high affinity for both 5-HT 2A and D 2 receptors; its 5-HT 2A binding 20 times greater than is D 2 binding (Fig. 2) . The 9-hydroxy metabolite has a binding profile that is similar to the parent compound. In rat brain tissue, risperidone is reported to bind to 5-HT 2A receptors with 20 times greater affinity and D 2 receptors with 50 times greater affinity than clozapine (39 striatum and mesolimbic areas of the brain, distinguishing it from the other compounds. The significance of this gradual occupancy curve has not been established, but it has been suggested that it contributes to a lower risk for EPS compared to conventional antipsychotics. Risperidone had a high binding affinity also for α 1 , α 2 , and H 1 receptors. This binding profile explains some of the more common adverse effects of risperidone: sedation and orthostasis.
Animal Studies
A variety of animal models have been used to investigate the efficacy and adverse effects of antipsychotic drugs. Catalepsy, for instance, can be induced in monkeys receiving compounds that antagonize striatal postsynaptic dopamine receptors. This pharmacological effect is believed to correlate closely with the risk for EPS in humans. Alternatively, the therapeutic effects of antipsychotic compounds are believed to correlate with their ability to block hyperactivity and stereotypy in animals pretreated with dopamine agonists (4,35). The hyperactivity response to dopamine agonists is mediated through the mesolimbic dopamine pathways, while dopamine agonist-induced stereotypies represent striatal activity. However, tests for blockade of both types of behavior are used to assess potential antipsychotic efficacy. Ideally, in animal models, atypical antipsychotics at therapeutic doses would block dopamine agonist-induced hyperactivity while having no effect on stereotypies and no induction of catalepsy. In fact, in one study, clozapine was found to block hyperactivity while actually increasing the stereotypic response to dopamine agonists (57) .
Studies of the pharmacological activity of risperidone in these animal models reveal an intriguing profile. Risperidone produces catalepsy only at very high doses (3 mg/kg) in rats. The drug also blocks dopamine agonist-induced agitation/hyperactivity and stereotypy in animal models (31) . Thus, at least at doses that are clinically relevant, risperidone appears to demonstrate efficacy with minimal risk for EPS in animal models. Some authors have proposed that risperidone may improve dopaminergic function in the mesocortical tract via selective blockade of 5-HT 2 receptors, through feedback loops with sero-CNS Drug Reviews, Vol. 5, No. 3, 1999 RISPERIDONE 253 tonin modulating dopamine release in this area (16, 29) . Furthermore, they suggest that 5-HT 2 blockade in the basal ganglia could enhance dopaminergic transmission in the nigrostriatal tract, thereby minimizing EPS. Thus, a drug such as risperidone could antagonize D 2 receptors in the mesolimbic tract, improving positive symptoms of schizophrenia, while simultaneously enhancing dopaminergic transmission through the mesocortical and nigrostriatal tracts, affecting negative symptoms and EPS, respectively. This theoretical explanation of the pharmacologic effects of risperidone is largely based on receptor densities in the areas described, however, and has yet to be demonstrated definitively.
PET Studies
In recent years, researchers have begun to quantify receptor binding in living human brains through the use of PET studies. This type of research provides the most accurate and clinically relevant pharmacological data available. In one study of four subjects with schizophrenia, risperidone 6 mg/d was found to induce 79% D 2 receptor occupancy and 86% 5-HT 2A receptor occupancy (18) . All subjects had a demonstrated benefit in psychotic symptoms; mild EPS were reported. In another report, researchers compared a risperidone 3 to 6 mg/d in seven subjects with schizophrenia. The lower dose produced antipsychotic efficacy, with D 2 receptor occupancy of 72% and 5-HT 2A receptor occupancy of 83 percent, with a lower incidence of EPS than that seen with risperidone 6 mg/d (52) . They concluded that a dose of 6 mg/d may be higher than necessary and recommend starting at 4 mg/d.
PHARMACOKINETICS Absorption
Risperidone is rapidly and completely absorbed after oral administration (26) . Food decreases the rate but not the overall extent of absorption (23) . Peak plasma levels occur within 1 h after oral administration. Bioavailability of the parent compound is approximately 65-70%, the majority of the rest of an oral dose undergoes first pass metabolism to 9-OH-risperidone (23, 26) . If risperidone and 9-OH-risperidone are considered together as the active moiety, the oral bioavailability increases to 100%. Approximately 90% of the parent compound and 77% of the 9-hydroxy metabolite are protein bound (45) . The volume of distribution of risperidone is approximately 0.7 L/kg, while the volume of distribution of 9-OH-risperidone is approximately 0.8 L/kg.
Metabolism
The cytochrome P450 IID6 isozyme metabolizes risperidone in a linear fashion via 9-hydroxylation, 7-hydroxylation, and oxidative N-dealkylation (26) . The 9-hydroxylation pathway predominates, producing the active 9-OH-risperidone metabolite. J. LOGAN 
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Since the IID6 isozyme is subject to genetic polymorphism, the metabolism of risperidone to 9-OH-risperidone can vary extensively among patients (23, 28) . Approximately 90% of Caucasians and up to 99% of Asians are extensive metabolizers at the IID6 isozyme. In extensive metabolizers, a relatively large portion of a dose of risperidone is converted to the 9-OH-risperidone metabolite, and the parent compound has a mean terminal half-life of about 3 h. Alternatively, in poor metabolizers, formation of the 9-hydroxy metabolite is much slower, and the parent compound has been observed to have a much longer plasma elimination half-life (up to 22 h).
Fortunately, the polymorphism is of little consequence in the clinical setting. When risperidone and the 9-OH-risperidone metabolite are considered together as the active moiety, cumulative differences in clearance and half-life are negligible (23, 28) . Regardless of whether subjects are extensive or poor metabolizers at the IID6 enzyme step, the active moiety is cleared consistently with a terminal elimination half-life of approximately 20 h. Plasma concentrations do not differ based on metabolic status.
Elimination
Approximately 10% of a dose of risperidone is excreted unchanged in the urine (23) . Sixty percent is excreted as metabolites in the urine, with up to one half of this being the predominant 9-OH-risperidone metabolite. The majority of the remainder of elimination is through the fecal route, with 15% of a dose excreted as metabolites in the feces. Virtually none of the dose is excreted unchanged in the feces, suggesting nearly complete absorption of the drug after oral dosing.
Clearance of 9-OH-risperidone is reduced in the elderly and those patients with diminished creatinine clearance. Furthermore, the half-life of the active moiety is extended from approximately 20 to 25 h in both of these groups of patients. In patients with liver disease leading to an impairment of plasma albumin levels, the unbound fraction of this extensively protein-bound drug (both risperidone and 9-OH-risperidone) can be increased. Thus, caution should be used in dosing and titrating risperidone in the elderly and those patients with renal or hepatic disease (26) .
Accumulation
In a naturalistic study of 24 patients treated with risperidone for up to 16 months, researchers measured morning blood concentrations of the parent drug and active metabolite on a bimonthly basis starting 7 to 14 days after dosage stabilization (14) . They found that risperidone concentrations increased over the first months to a peak concentrations of 334% greater than the starting levels and before leveling off. Concentrations of 9-OH-risperidone peaked at a 104% increase over the first 6 months. Concentrations of the active moiety (risperidone and 9-OH-risperidone) peaked at 111% of the baseline concentrations over the first 6 months and then declined over the next 6 months, ultimately stabilizing 31% higher than the baseline concentration. Importantly, the authors found significant variation in blood levels among individuals and among measurements for the same individual. These results suggest that fixed dose approaches to treatment with risperidone may not be optimal in all patients. Fluctuations in plasma concentrations may also render routine therapeutic drug monitoring practices impractical.
CLINICAL EFFICACY

Comparison with Conventional Antipsychotics
Risperidone was approved by the United States Food and Drug Administration in 1994 for "the treatment of psychotic symptoms." This decision was influenced, primarily, by acceptable safety and efficacy data emanating from short-term randomized controlled trials comparing the effects of risperidone to placebo and/or haloperidol in patients with schizophrenia. While this particular study design is helpful for minimizing selection and treatment biases and is commonly employed for phase III trials, caution is advised in generalizing these results to actual practice settings (59) .
To date, there have been nine published randomized controlled trials comparing the effects of risperidone to conventional antipsychotics (seven with haloperidol, and one each with fluphenzine and zuclopenthixol) in patients diagnosed with schizophrenia or schizophreniform disorder (6, 8, 10, 11, 27, 30, 47, 49, 53) . A total of 3029 subjects were included in these investigations and the duration of treatment ranged from 4-12 weeks. Most of these trials feature fixed-dose regimens of risperidone, and results appear to indicate that daily doses of 4-16 mg are at least comparable to conventional antipsychotics in alleviating psychotic symptoms. A meta-analysis of six comparative trials with haloperidol (9-20 mg/d) reported that risperidone (4-8 mg/d) was clinically superior to the conventional agent, with a mean difference of 13.9% in response rates (defined as a > 20% reduction in the Positive and Negative Symptom Scale (PANSS) or Brief Psychiatric Rating Scale (BPRS); 95% confidence interval of 5.6-22.3%) (15) .
The impact of risperidone on the negative symptoms of schizophrenia appeared to be significant in these clinical trials as well. A factor analysis of pooled data from the North American Risperidone Trials (NART) concluded that all four of the risperidone dosing regimens (2, 6, 10, and 16 mg/d) were significantly more effective than haloperidol (20 mg/d) in relieving negative symptoms (46) . This benefit appeared to be independent of EPS, suggesting that risperidone was addressing the primary negative symptoms of schizophrenia as opposed to the secondary negative symptoms of medication side effects.
The cognitive effects of risperidone in patients with schizophrena haved also been studie. In comparison to haloperidol, risperidone demonstrated a more beneficial effect on verbal memory at the end of a 4-week trial (22) . Another study examined the effects of risperidone on perceived emotion in subjects with treatment-resistant schizophrenia (34) . Patients receiving risperidone performed much better than those prescribed haloperidol and, even with control for improvements in positive symptoms, these beneficial effects persisted. Other investigations have reported improved alertness and attention with risperidone and superior performances in multitask operations (21, 62) .
Tolerability data from the clinical trials suggest that the side effect burden attributed to risperidone is comparatively low, especially with daily doses of 8 mg or less. Dropout rates were significantly less for patients receiving risperidone in the results of the meta-analysis cited previously (12.7% difference; with 95% confidence limits of 4.3-21.2%) (15) . The risk for EPS, in particular, is a dose-dependent phenomenon with risperidone, as the drug appears to lose its relative specificity (or "atypicality") at higher doses. Within the usual therapeutic range, however, risperidone-treated subjects were much less likely to experience EPS than subjects treated with conventional compounds (10, 47) .
Comparison with Other Atypical Antipsychotics
As atypical antipsychotics have been widely embraced as first line agents for the treatment of schizophrenia, the clinical differences among these agents have emerged as a pressing issue. Unfortunately, few head-to-head comparisons of the atypical antipsychotics have been published, and the available results have been largely inconclusive.
Three studies have been conducted comparing the therapeutic effects of risperidone to clozapine in the treatment of psychotic symptoms (7, 25, 37) . Each of these investigations concluded that the medications were equally effective, but these findings are tempered somewhat by significant limitations in study design, including a small number of enrolled subjects and brief duration of treatment. The largest of these investigations was an 8-week trial examining the outcome of 86 subjects randomized to risperidone (average daily dose = 6.4 mg) or clozapine (average daily dose = 291.2 mg) (7). At endpoint, 67% of the risperidone-treated patients and 65% of the clozapine-treated patients were considered to be clinically improved (defined as > 20% reduction on total PANSS scores). The authors reported a much more rapid response with risperidone and better tolerability with this medication as well. A more recent 12-week open-label trial demonstrated therapeutic superiority with clozapine, raising the possibility that brief study periods may have limited the apparent clinical effectiveness of clozapine in previous trials (40) .
Two investigations have compared the clinical benefits of risperidone to olanzapine (13, 64) . The first investigation was a 28-week, double-blind study analyzing the therapeutic effects and tolerability of these two atypical agents in 339 subjects with schizophrenia or other psychotic disorders (64) . Overall response rates (> 20% reduction in total PANSS score) were comparable between the two medications at endpoint (63.0% with risperidone vs. 61.5% with olanzapine), but olanzapine appeared to have a greater impact than risperidone on negative symptoms (Scale for Assessment of Negative Symptoms (SANS); P < 0.02). Both medications were commonly associated with weight gain and substantial increases in prolactin concentrations, while the incidence of EPS effects was significantly higher in patients receiving risperidone.
An 8-week, randomized, controlled trial comparing the effects of risperidone to olanzapine for the treatment of psychotic disorders in 407 subjects was recently concluded (13) . The average daily dose of risperidone employed in this study was lower and more consistent with actual practice patterns (4.6 vs. 7.2 mg) than the study summarized above and study findings were quite different as well. Treatment response rates (defined as > 30% reduction in total PANSS score) were significantly higher for patients randomized to risperidone (27%) than for olanzapine (21%; P < 0.05). EPS were relatively uncommon in both treatment arms, but olanzapine was associated with a bigger increase in total body weight (P < 0.001).
Other Indications
The attractive side effect profile and unique pharmacological effects of risperidone and other atypical antipsychotics have led researchers and clinicians to consider their utility for treating other neuropsychiatric conditions as well. Risperidone has become a valuable alternative for the treatment of behavioral disturbances associated with Alzheimer's disease and other dementias (20, 32, 67) . A large double-blind, randomized, placebo-controlled trial published earlier this year examined the effects of various fixed doses of risperidone (0.5, 1, and 2 mg/d) on psychotic and aggressive symptoms among 625 patients with severe dementia (32) . Based on changes in Behavioral Pathology in Alzheimer's Disease (BEHAVE-AD) scores after 12 weeks of treatment, daily doses of 1 mg and 2 mg were significantly more effective than placebo on both outcome measures (P = 0.005 and P < 0.001, respectively), and 0.5 mg/d was superior to placebo for the treatment of aggression (P = 0.02). As patients receiving the 2 mg/d dose were more likely to discontinue treatment due to side effects (24% dropout rate compared to 16% with 1 mg/d), the authors speculated that 1 mg/d would be the most appropriate regimen for managing these behavioral disturbances.
Anecdotal reports and open-label trials suggest that risperidone may also relieve symptoms associated with autism, Tourette's syndrome, mental retardation, and certain affective disorders (33, 42, 43, 48, 63) . Small uncontrolled studies have evaluated the use of risperidone as an adjunct to serotonin reuptake inhibitors (SSRIs) for obsessive-compulsive disorder (OCD) or refractory bipolar disorder (54, 58) . Others have suggested that the effect of risperidone on postsynaptic 5-HT 2 receptors may be helpful for managing depression with psychotic features (12, 58) . Controlled studies are needed to further evaluate the role of risperidone in these other illnesses.
COST EFFECTIVENESS
While risperidone possesses distinct clinical advantages over older antipsychotic medications, the acquisition cost for this atypical agent is considerably higher, inspiring researchers and health economists to study the wisdom of this investment. A variety of investigations have examined the impact of risperidone on direct treatment costs, and the vast majority of these studies have concluded that the medication was cost-effective due, ostensibly, to robust declines in reported hospitalization rates (1,2,19,41,50,65) . Unfortunately, all of these studies have been retrospective in nature and most have merely tracked the progress of small cohorts of responsive patients (i.e., mirror-image design), failing to compare outcomes to those of matched controls.
One research group took a more novel approach to the cost-effectiveness issue, incorporating data from the North American Risperidone Trial into a cost-utility analysis (9) . The apparent quality of life for enrolled subjects was estimated at baseline and endpoint (6 weeks) from symptom clusters presented to 100 psychiatric nurses. The gain in utility ratings was 2.6 times higher for patients receiving risperidone (6 mg/d) than haloperidol (20 mg/d) and the differential cost for risperidone was $24,250 per quality adjusted life year (QALY) in Canadian dollars. Ordinarily, this figure would imply that the intervention (risperidone) is cost-effective but one must recall that utility ratings in this study were measured retrospectively from a 6-week course of treatment and subsequently projected out to 1 full year of therapy. As the patient's perspective and quality of life have strong influences upon medication compliance rates and clinical outcomes, it is hoped that costutility analyses are considered in future health economic research with risperidone.
SAFETY AND TOXICOLOGY
Overall, risperidone has been fairly well tolerated in large-scale studies with only 7% of subjects in the 4-8 mg/d dosage range dropping out due to medication side effects. Based on placebo-adjusted rates, the most common acute adverse effects appear to be sedation, orthostasis/dizziness, agitation, insomnia, difficulty concentrating, asthenia, and headache. Fortunately, these adverse effects tend to be mild and transient, and conservative dosage titration practices have further minimized the severity of these sequelae.
Qualitatively, the adverse effects associated with chronic or long-term use may be considerably different from acute experiences and consist of weight gain, EPS, and adverse effects associated with increased prolactin. Substantial weight gain can be encountered with all of the atypical antipsychotics and appears to be more common than incidences historically reported for conventional compounds. One prospective study, in fact, reported an average weight gain of approximately 14 pounds after 16 weeks of clozapine treatment (38) . This effect has been attributed to the high affinity atypical agents have for blocking the 5-HT 2C serotonin receptor, and in vitro data suggest that clozapine possesses the highest affinity, followed by olanzapine, risperidone, and quetiapine, respectively (Table 1) . In vivo evidence supports this hierarchy (3) . Since this is believed to be a dosedependent phenomenon, dosage reduction (when possible) may limit the degree of weight gain and behavioral modification has been emphasized as well.
EPS have been reported with risperidone but, as mentioned previously, the incidence is relatively low with doses commonly used to treat schizophrenia. The elderly appear to be particularly sensitive to this effect and can experience akathisia or parkinsonism with doses as low as 2 mg/d. This predisposition may be due to reduced metabolic rates (i.e., increased plasma concentrations) as well as age-related changes in nigrostriatal activity.
Like conventional antipsychotics, risperidone can induce significant increases in circulating prolactin concentrations. This hormonal effect is a product of potent blockade of postsynaptic D 2 receptors and is, therefore, more pronounced with higher doses of risperidone. Clinical manifestations of prolactin increase are uncommon but can include decreased libido, gynecomastia, galactorrhea, and amenorrhea (36) . These effects are reversible upon treatment discontinuation.
DOSING AND ADMINISTRATION
Since risperidone was originally marketed, significant changes in dosing practices have occurred. For the treatment of psychotic symptoms, the manufacturers originally recommended that clinicians initiate therapy at 1 mg twice daily, increasing to 2 mg twice daily on the second day and advancing to 3 mg twice daily on the third day (55) . Clinicians soon found this titration method to be rather rapid, resulting in occasional dizziness or sedation.
The average daily dose of risperidone for patients with schizophrenia is currently 4.8 mg in the United States, reflecting a more conservative approach to titration. In practice, many clinicians will start the medication with 1 mg/d at bedtime and gradually titrate up to 4 mg/d over the first week, monitoring patient progress over the next few weeks (44) . If patients respond to this dose, it may be given once daily as a single tablet, resulting in improved compliance and substantial cost savings (24) . If necessary, additional dosage increases should be made in increments of 1 mg/d or less and it is relatively uncommon for patients to receive more than 6 mg/d.
According to the manufacturer, the dosage requirements of elderly patients are roughly half that of the general population (56) . When prescribed for the management of behavioral disturbances associated with dementia, risperidone therapy should be started with a bedtime dose of 0.25-0.50 mg and increased to 1 mg if indicated. Higher doses are associated with a substantial increase in the incidence of EPS, and the anticipated benefits should be carefully weighed against these risks (32) .
DISCUSSION
Since the 1950s, schizophrenia has been treated with blunt instruments of nonselective D 2 receptor blockade, the conventional antipsychotics. Just as an increased understanding of the disease processes in areas such as oncology have allowed the development of more elegant, finely-tuned therapies (such as monoclonal antibodies and gene therapies), clinicians should hold forth for more refined tools for the treatment of psychiatric illnesses. The discovery of the beneficial effects of 5-HT 2A antagonism in conjunction with moderate D 2 antagonism has spurred a flood of research into the neurochemical and anatomic mechanisms of schizophrenia.
Atypical antipsychotics have been defined by a variety of factors, including anatomic specificity for the mesolimbic system, low D 2 receptor occupancy relative to 5-HT 2A occupancy, and a separation of dose-response curves for therapeutic efficacy vs. EPS. This low risk for EPS at clinically relevant doses is the definition most often used. By this definition, risperidone is the second atypical antipsychotic introduced on the U.S. market and, as such, holds a place of significance in the development of our understanding of the pathogenesis and treatment of schizophrenia.
Dopamine blockade in the mesolimbic tract appears to treat the positive symptoms of schizophrenia. On the other hand, dopamine blockade in the other tracts affected by antipsychotics leads to the all too familiar Parkinsonian side effects (nigrostriatal), hyperprolactinemia (tuberoinfundibular), and possibly a worsening of negative symptoms (mesocortical). While the treatment of positive symptoms results in the most conspicuous effects of antipsychotic therapy, EPS or untreated negative symptoms can worsen patient noncompliance, ultimately leading to treatment discontinuation. Thus, while the development of more specific, selective treatments for schizophrenia will improve patients' quality of life, it will also improve compliance, overall treatment rates, and the cost-effectiveness of treatment.
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Risperidone represents an early, important step in this process. The majority of atypical antipsychotics developed since its release have focused on the characteristic pattern of risperidone: of high 5-HT 2A affinity in conjunction with a moderate to high affinity for D 2 receptors. This drug has been well tolerated in clinical trials with a very low risk of producing EPS in clinically relevant doses. Recent PET studies in subjects with schizophrenia have suggested that a 3 mg dose is sufficient to induce significant D 2 receptor occupancy, with demonstrated efficacy for psychotic symptoms and a low incidence of EPS. Currently, the average dose of risperidone used in the United States is 4.8 mg/d, within the range of the maximal clinical benefits seen in controlled studies.
The role of 5-HT 2A antagonism in lowering EPS liability and ameliorating negative symptoms has yet to be established. A model for dopamine modulation by 5-HT receptors in the mesocortical tract, leading to improvement of negative symptoms, has been described. Unfortunately, treatment of negative symptoms by risperidone has not been demonstrated unequivocally. Some studies have reported improvement in negative symptoms, while others have not (10, 47, 53) . Thus, both the effects at a neurotransmitter receptor level and the potential beneficial effects of this agent on the mesocortical tract remain theoretical. At lower doses, risperidone has a lower D 2 receptor occupancy, apparently sufficient to treat positive symptoms, yet insufficient to increase the risk for EPS by dopamine blockade in the nigrostriatal tract. This decreased effect in the nigrostriatal tract also may be a result of the 5-HT 2A modulation of dopamine release in this area, but this fact has not been demonstrated. Dopamine blockade in the tuberoinfundibular tract sufficient to induce hyperprolactinemia does occur with risperidone at clinically relevant doses.
As research methods improve and more clinical experience is gained with atypical antipsychotic agents such as risperidone, the broad knowledge base about disease pathology and neurochemistry of schizophrenia will provide the foundation for developing the ideal atypical agent (or combination of agents) to produce significant improvement in positive and negative symptoms with little risk of EPS or tardive dyskinesia. Risperidone, with its low risk of EPS and high level of tolerability, has had a tremendous impact in improving medication compliance and patient quality of life among schizophrenics. As such, it has played a significant role in strengthening this foundation.
